{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:46:43Z","timestamp":1793825203730,"version":"4.6.1"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:sec id=\"ab-eoi250027-4\"><jats:title>Importance<\/jats:title><jats:p>Understanding the relationship between longitudinally measured systemic complement factors and intermediate AMD (iAMD) progression may enable the introduction of systemic therapeutics earlier in the disease course, before vision loss occurs.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250027-5\"><jats:title>Objective<\/jats:title><jats:p>To determine the contribution of longitudinal measures of systemic complement factors and ratios to time to progression to advanced AMD (geographic atrophy [GA] or neovascular AMD [NVAMD]).<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250027-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This cohort study was conducted at Sue Anschutz Rodgers Eye Center, Aurora, Colorado, from 2014 to 2022. Participants were patients with iAMD and at least 1 month of follow-up. Data analysis was performed from September to December 2024.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250027-7\"><jats:title>Exposures<\/jats:title><jats:p>Complement factors.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250027-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Time to progression to advanced AMD, either GA or NVAMD. Joint models were used to estimate the relationship between the exposures and the outcomes. The hazard ratio (HR) was a measure of association.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250027-9\"><jats:title>Results<\/jats:title><jats:p>Among 325 participants, the mean (SD) age was 76 (7.0) years; 212 participants (65%) were female and 113 (35%) male. During the 8-year follow-up period (mean, 3.9 years), 110 participants (34%) progressed to any advanced AMD. Sixty-four participants (20%) progressed to GA and 46 (14%) to NVAMD. Higher systemic levels of C4 (HR, 6.8; 95% credible interval [CrI], 1.7-26.2; <jats:italic>P<\/jats:italic>\u2009=\u2009.03), C4b (HR, 60.4; 95% CrI, 6.5-544; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001), C3a\/C3 (HR, 49.4; 95% CrI, 5.2-675; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001), C5a\/C5 (HR, 29.3; 95% CrI, 4.8-258; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001), sC5b-9\/C5 (HR, 297; 95% CrI, 10-14\u202f877; <jats:italic>P<\/jats:italic>\u2009=\u2009.003), and factor I (HR, 525.9; 95% CrI, 5.5-107\u202f589; <jats:italic>P<\/jats:italic>\u2009=\u2009.02) were associated with shorter time to progression to any AMD. Levels of C3a\/C3 (HR, 9.5; 95% CrI, 1.9-55.9; <jats:italic>P<\/jats:italic>\u2009=\u2009.01) and C5a\/C5 (HR, 28.6; 95% CrI, 5.7-157.9; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) were associated with the hazard of GA.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250027-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Continued dysregulation of complement pathways appears to increase the hazard of iAMD progression. This supports the possibility of identifying a high-risk group of patients with iAMD for personalized ophthalmic care and targeted treatments to attenuate the risk of iAMD progression.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2025.1608","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T11:01:14Z","timestamp":1749726074000},"page":"634","source":"Crossref","is-referenced-by-count":6,"title":["Dynamic Risk of Systemic Complement Activation With Time to Progression to Advanced Age-Related Macular Degeneration"],"prefix":"10.1001","volume":"143","author":[{"given":"Anne M.","family":"Lynch","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan C.","family":"Grove","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandie D.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Informatics, University of Colorado School of Public Health, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan G.","family":"Palestine","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Michael","family":"Holers","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado School of Medicine, Aurora"},{"name":"Department of Immunology, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley A.","family":"Frazer-Abel","sequence":"additional","affiliation":[{"name":"Exsera BioLabs, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Gnanaraj","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Lisker-Cervantes","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Patnaik","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talisa E.","family":"de Carlo Forest","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Auer","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arden J.","family":"McReynolds","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc T.","family":"Mathias","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Manoharan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Rodriquez De Cordoba","sequence":"additional","affiliation":[{"name":"Department of Molecular Biomedicine, Centro de Investigaciones Biol\u00f3gicas, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Mandava","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"eoi250027r1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"2","key":"eoi250027r2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review.","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"eoi250027r3","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","article-title":"Clinical classification of age-related macular degeneration.","volume":"120","author":"Ferris","year":"2013","journal-title":"Ophthalmology"},{"key":"eoi250027r4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.preteyeres.2016.04.003","article-title":"Risk factors and biomarkers of age-related macular degeneration.","volume":"54","author":"Lambert","year":"2016","journal-title":"Prog Retin Eye Res"},{"issue":"11","key":"eoi250027r5","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.imbio.2012.07.021","article-title":"Complement dysregulation and disease: from genes and proteins to diagnostics and drugs.","volume":"217","author":"de Cordoba","year":"2012","journal-title":"Immunobiology"},{"issue":"7","key":"eoi250027r6","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ophtha.2017.12.023","article-title":"Genome-wide association study reveals variants in CFH and CFHR4 associated with systemic complement activation: implications in age-related macular degeneration.","volume":"125","author":"Lor\u00e9s-Motta","year":"2018","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi250027r7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S1350-9462(01)00010-6","article-title":"An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch\u2019s membrane interface in aging and age-related macular degeneration.","volume":"20","author":"Hageman","year":"2001","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"eoi250027r8","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/eye.2016.328","article-title":"Local complement activation in aqueous humor in patients with age-related macular degeneration.","volume":"31","author":"Schick","year":"2017","journal-title":"Eye (Lond)"},{"key":"eoi250027r9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.exer.2015.09.003","article-title":"Selective accumulation of the complement membrane attack complex in aging choriocapillaris.","volume":"146","author":"Chirco","year":"2016","journal-title":"Exp Eye Res"},{"issue":"4","key":"eoi250027r10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.exer.2011.06.015","article-title":"Elevated membrane attack complex in human choroid with high risk complement factor H genotypes.","volume":"93","author":"Mullins","year":"2011","journal-title":"Exp Eye Res"},{"key":"eoi250027r11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2014.11.005","article-title":"Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy.","volume":"45","author":"Whitmore","year":"2015","journal-title":"Prog Retin Eye Res"},{"issue":"8","key":"eoi250027r12","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1080\/07853890601097030","article-title":"Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications.","volume":"38","author":"Hageman","year":"2006","journal-title":"Ann Med"},{"issue":"2","key":"eoi250027r13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants.","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nat Genet"},{"key":"eoi250027r15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1146\/annurev-immunol-032713-120154","article-title":"Complement and its receptors: new insights into human disease.","volume":"32","author":"Holers","year":"2014","journal-title":"Annu Rev Immunol"},{"issue":"10424","key":"eoi250027r16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S0140-6736(23)01524-6","article-title":"Complement in human disease: approved and up-and-coming therapeutics.","volume":"403","author":"West","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"eoi250027r17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1177\/1120672119857896","article-title":"Systemic activation of the complement system in patients with advanced age-related macular degeneration.","volume":"30","author":"Lynch","year":"2020","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"eoi250027r18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1167\/tvst.11.5.22","article-title":"Sex and age-related differences in complement factors among patients with intermediate age-related macular degeneration.","volume":"11","author":"Marin","year":"2022","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"eoi250027r19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2019-000361","article-title":"Complement factors and reticular pseudodrusen in intermediate age-related macular degeneration staged by multimodal imaging.","volume":"5","author":"Lynch","year":"2020","journal-title":"BMJ Open Ophthalmol"},{"issue":"12","key":"eoi250027r20","doi-asserted-by":"publisher","first-page":"5818","DOI":"10.1167\/iovs.09-3928","article-title":"Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes.","volume":"50","author":"Reynolds","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"eoi250027r21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1001\/archopht.125.4.515","article-title":"Estimation of systemic complement C3 activity in age-related macular degeneration.","volume":"125","author":"Sivaprasad","year":"2007","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"eoi250027r22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002593","article-title":"Systemic complement activation in age-related macular degeneration.","volume":"3","author":"Scholl","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"eoi250027r23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000219686","article-title":"Elevated plasma levels of C3a complement compound in the exudative form of age-related macular degeneration.","volume":"42","author":"Machalinska","year":"2009","journal-title":"Ophthalmic Res"},{"issue":"3","key":"eoi250027r24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093459","article-title":"Impact of the common genetic associations of age-related macular degeneration upon systemic complement component C3d levels.","volume":"9","author":"Ristau","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"eoi250027r25","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ophtha.2011.07.056","article-title":"Risk alleles in CFH and ARMS2 are independently associated with systemic complement activation in age-related macular degeneration.","volume":"119","author":"Smailhodzic","year":"2012","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi250027r26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1167\/iovs.61.3.18","article-title":"Complement activation levels are related to disease stage in AMD.","volume":"61","author":"Heesterbeek","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"eoi250027r27","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2022.100118","article-title":"Systemic complement activation profiles in nonexudative age-related macular degeneration: a systematic review.","volume":"2","author":"Lin","year":"2022","journal-title":"Ophthalmol Sci"},{"issue":"9","key":"eoi250027r28","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.3390\/jcm11092371","article-title":"Systemic complement activation profiles in nonexudative age-related macular degeneration: a meta-analysis.","volume":"11","author":"Lin","year":"2022","journal-title":"J Clin Med"},{"issue":"12","key":"eoi250027r29","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"issue":"8","key":"eoi250027r30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/tvst.12.8.1","article-title":"Interleukin-4 plasma levels stratified by sex in intermediate age-related macular degeneration and geographic atrophy.","volume":"12","author":"Rajeswaren","year":"2023","journal-title":"Transl Vis Sci Technol"},{"issue":"4","key":"eoi250027r31","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1097\/IAE.0000000000002023","article-title":"Colorado Age-Related Macular Degeneration Registry: design and clinical risk factors of the cohort.","volume":"39","author":"Lynch","year":"2019","journal-title":"Retina"},{"issue":"3","key":"eoi250027r32","first-page":"484","article-title":"Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation.","volume":"73","author":"Mollnes","year":"1988","journal-title":"Clin Exp Immunol"},{"key":"eoi250027r33","doi-asserted-by":"publisher","DOI":"10.1080\/09286586.2024.2428193","article-title":"Loss to follow-up in intermediate age-related macular degeneration patients enrolled in the University of Colorado AMD Registry.","author":"McReynolds","year":"2024","journal-title":"Ophthalmic Epidemiol"},{"issue":"4","key":"eoi250027r34","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","article-title":"Consensus definition for atrophy associated with age-related macular degeneration on OCT: Classification of Atrophy Report 3.","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi250027r35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practival and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B"},{"issue":"11","key":"eoi250027r36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1167\/iovs.61.11.39","article-title":"Complement activation in the vitreous of patients with proliferative diabetic retinopathy.","volume":"61","author":"Mandava","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"eoi250027r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2021.108460","article-title":"Increased ratios of complement factors C3a to C3 in aqueous humor and serum mark glaucoma progression.","volume":"204","author":"Hubens","year":"2021","journal-title":"Exp Eye Res"},{"issue":"5","key":"eoi250027r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2023.152410","article-title":"Complement factor I: regulatory nexus, driver of immunopathology, and therapeutic.","volume":"228","author":"Hallam","year":"2023","journal-title":"Immunobiology"},{"issue":"1","key":"eoi250027r39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13024-018-0278-0","article-title":"Subretinal macrophages produce classical complement activator C1q leading to the progression of focal retinal degeneration.","volume":"13","author":"Jiao","year":"2018","journal-title":"Mol Neurodegener"},{"issue":"1","key":"eoi250027r40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40942-022-00431-y","article-title":"C1q and the classical complement cascade in geographic atrophy secondary to age-related macular degeneration.","volume":"8","author":"Yednock","year":"2022","journal-title":"Int J Retina Vitreous"},{"issue":"10411","key":"eoi250027r41","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/S0140-6736(23)01844-5","article-title":"Complement inhibitors for the treatment of geographic atrophy.","volume":"402","author":"Chew","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"eoi250027r42","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial.","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"issue":"10411","key":"eoi250027r43","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"issue":"17","key":"eoi250027r44","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1038\/s41433-023-02497-w","article-title":"Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.","volume":"37","author":"Patel","year":"2023","journal-title":"Eye (Lond)"},{"issue":"4","key":"eoi250027r45","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial.","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi250027r46","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.survophthal.2023.11.008","article-title":"The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: a living systematic review and meta-analysis.","volume":"69","author":"Garg","year":"2024","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"eoi250027r47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/24741264231220224","article-title":"Retinal vasculitis after intravitreal pegcetacoplan: report from the ASRS Research and Safety in Therapeutics (ReST) Committee.","volume":"8","author":"Witkin","year":"2023","journal-title":"J Vitreoretin Dis"},{"issue":"1","key":"eoi250027r48","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2024-001854","article-title":"New horizons in geographic atrophy treatment: enthusiasm and caution surrounding complement inhibitors.","volume":"9","author":"Lai","year":"2024","journal-title":"BMJ Open Ophthalmol"},{"issue":"9","key":"eoi250027r49","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.ophtha.2021.02.025","article-title":"Characterizing new-onset exudation in the randomized phase 2 FILLY trial of complement inhibitor pegcetacoplan for geographic atrophy.","volume":"128","author":"Wykoff","year":"2021","journal-title":"Ophthalmology"},{"key":"eoi250027r51","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2024.109885","article-title":"Retinal microcirculation: a window into systemic circulation and metabolic disease.","volume":"242","author":"Yuan","year":"2024","journal-title":"Exp Eye Res"},{"issue":"Pt 2","key":"eoi250027r52","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/eye.1990.41","article-title":"Permeability of ocular vessels and transport across the blood-retinal-barrier.","volume":"4","author":"T\u00f6rnquist","year":"1990","journal-title":"Eye (Lond)"},{"issue":"2","key":"eoi250027r53","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.preteyeres.2009.12.002","article-title":"The multifunctional choroid.","volume":"29","author":"Nickla","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"eoi250027r14","first-page":"55","volume-title":"Immunobiology: the Immune System in Health and Disease","author":"Janeway","year":"2005","edition":"6th ed"},{"key":"eoi250027r50","unstructured":"ClinicalTrials.gov, Regeneron Pharmaceuticals. A study investigating subcutaneously administered pozelimab in combination with cemdisiran or cemdisiran alone in adult participants with geographic atrophy (SIENNA) [interventional study; NCT06541704]. Accessed May 8, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06541704?cond=Age%20Related%20Macular%20Degeneration%20Cemdisiran&term=regeneron&rank=1."}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2835224\/jamaophthalmology_lynch_2025_oi_250027_1754685066.05289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T15:00:46Z","timestamp":1755788446000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2835224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.1608","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}